Becotatug vedotin clinical trials
Also written MRG003.
How each study uses becotatug vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the becotatug vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MRG003
- 17
Studies by the year they started
61 studies that test it; most in 2026 (50); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 50 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 52
Lepu Biopharma Co., Ltd. (10) · Sun Yat-sen University (10) · Fudan University (7) · Tianjin Medical University Cancer Institute and Hospital (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · West China Hospital (2) · Jiyan Liu (2)
Often tested with
Tested in the same studies.
Pucotenlimab (21) · Immune checkpoint inhibitors (3) · Ado-Trastuzumab Emtansine (1) · Trastuzumab deruxtecan (1) · Datopotamab deruxtecan (1) · Sacituzumab govitecan (1) · Enfortumab vedotin (1) · Izalontamab brengitecan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 15
Studies that test becotatug vedotin.
- Dec 2026ADC and SBRT for Recurrent/Metastatic Salivary Gland CarcinomaPhase 2 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Dec 2026A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell CarcinomaPhase 2 · Lei Liu
- Mar 2027Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)Phase 2 · Shanghai Zhongshan Hospital
- Mar 2027A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal CancerPhase 2 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Mar 2027Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2Phase 2 · Tianjin Medical University Cancer Institute and Hospital
- May 2027Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsPhase 1 · Sun Yat-sen University
- Jun 2027Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaPhase 2 · Sun Yat-sen University
- Aug 2027A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsPhase 1/2 · Lepu Biopharma Co., Ltd.
- Aug 2027Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.Phase 2 · Hongmeng Yu
- Sep 2027Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerPhase 2 · Fudan University
Studies
Open first, then newest update. How each study uses becotatug vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 62
- Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCRecruitingPhase 3First Affiliated Hospital of Guangxi Medical UniversityNCT07459296Written as Becotatug Vedotin
- Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction ImmunochemotherapyNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07915258Written as Becotatug Vedotin (MRG003)
- Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07902713Written as Becotatug Vedotin (MRG003)
- Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07524413Written as Becotatug Vedotin
- Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract CancerEnrolling by invitationPhase 2Jiangmen Central HospitalNCT07890311Written as MRG003 (Becotatug Vedotin)
- Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard TherapyRecruitingNot applicableNingbo Medical Center Lihuili HospitalNCT07892573Written as Becotatug Vedotin
- Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later SettingRecruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT07892833Written as Becotatug vedotin (MRG003)
- Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLCNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07882940Written as Becotatug Vedotin (MRG003)+pucotenlimab+platinum
- Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerRecruitingPhase 2Fudan UniversityNCT07884188Written as Becotatug Vedotin (MRG003)
- MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPCRecruitingPhase 2Fujian Cancer HospitalNCT07331428Written as MRG003
- Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLCRecruitingNot applicableShanghai Pulmonary Hospital, Shanghai, ChinaNCT07874581Written as MRG003 (Becotatug Vedotin)
- MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07874321Written as Becotatug Vedotin (MRG003)
- ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCCNot yet recruitingPhase 2Huashan HospitalNCT07844551Written as Becotatug Vedotin (MRG003)
- A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile CancerRecruitingPhase 2Fudan UniversityNCT07497919Written as Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Becotatug vedotin (MRG003)
- A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 2West China HospitalNCT07381075Written as Becotatug Vedotin
- A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNRecruitingPhase 3Lepu Biopharma Co., Ltd.NCT05751512Written as MRG003
- A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Lepu Biopharma Co., Ltd.NCT05688605Written as MRG003+HX008
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaRecruitingPhase 3Lepu Biopharma Co., Ltd.NCT06976190Written as MRG003 + Pucotenlimab
- Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.RecruitingPhase 2Hongmeng YuNCT07781358Written as Becotatug Vedotin
See all 62 studies that test becotatug vedotin →
Given beside what is tested · 2 — becotatug vedotin is usual care or a partner of the new treatment
- Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingPhase 2West China Second University HospitalNCT07692334Written as Becotatug Vedotin (MRG003)
- Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and NeckRecruitingPhase 2Groupe Oncologie Radiotherapie Tete et CouNCT06959108Written as MRG003
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPCOct 19, 2026NCT07331428
Newly registered7
- Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction ImmunochemotherapyNov 4, 2026NCT07915258
- Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal CarcinomaOct 29, 2026NCT07902713
- Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard TherapyOct 23, 2026NCT07892573
- Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later SettingOct 23, 2026NCT07892833
- Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract CancerOct 22, 2026NCT07890311
Show 2 moreShow fewer
- Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLCOct 20, 2026NCT07882940
- Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerOct 20, 2026NCT07884188
Codes
What other systems call becotatug vedotin · ClinicalTrials.gg INT018246
- UNII (FDA) VHA6L8H5FMBECOTATUG VEDOTINOne source FDA
- NCI Thesaurus C180585Becotatug VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VHA6L8H5FM | BECOTATUG VEDOTIN | One source FDA |
| NCI Thesaurus | C180585 | Becotatug Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.